Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now later-stage tilt small index

Primary Sjogren's Disease: later-stage trial registry

2 of 2 indexed Primary Sjogren's Disease trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Primary Sjogren's Disease: 2 US clinical trials tracked, 2 recruiting.

Primary Sjogren's Disease is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Vor Biopharma, running 1 of these trials.

Enrollment posture brief

Registry condition primary-sjogrens-disease

OPEN 2 | RECR 100% | LATE 2 | EARLY 0 | RANK #7188 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Primary Sjogren's Diseas (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Primary Sjogren's Disease

Primary Sjogren's Disease lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Sjogren's Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Sjogren's Disease is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 32

Phase Distribution

PhaseTrial count
Phase 3 2

Top Sponsors

Vor Biopharma 1 trials
argenx 1 trials

Named interventions

Most-linked intervention names on Primary Sjogren's Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Efgartigimod PH20 SC Biological
1 trials
Telitacicept Biological
1 trials
Placebo PH20 SC Other
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Primary Sjogren's Disease trials. A trial with sites in several states counts in each.

Illinois 2 trials
Texas 1 trials
Louisiana 1 trials
Idaho 1 trials
Georgia 1 trials
Florida 1 trials
Colorado 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Sjogren's Disease page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Primary Sjogren's Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Vor Biopharma sponsors the most Primary Sjogren's Disease trials on record, review their full trial history before evaluating a specific study. See Vor Biopharma's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Sjogren's Disease condition card totals 2 registered trials; most-linked intervention Efgartigimod PH20 SC; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.